Here, we demonstrate that transient and chronic acidic-adapted melanoma cells express an anoikis resistance as a new additional trait, which may be targeted by mammalian target of rapamycin (mTOR)/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) inhibitors. This evidence concerns the gene NFKB1 and melanoma.